Components:
Erythromycin
Method of action:
Antibiotic Combination, Antitumour, Bacteriostatic
Available in countries
See all
close

Name of the medicinal product

A/T/S (Topical)

Qualitative and quantitative composition

Erythromycin

Pharmaceutical form

Gel/Jelly; Lotion; Ointment; Pad; Powder; Solution; Swab

Therapeutic indications

The information provided in Therapeutic indications of A/T/S (Topical) is based on data of another medicine with exactly the same composition as the A/T/S (Topical) of the medicine (Erythromycin). Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug A/T/S (Topical) directly from the package or from the pharmacist at the pharmacy.
more... close

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin.

For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis.

The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established.

For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.

Dosage (Posology) and method of administration

The information provided in Dosage (Posology) and method of administration of A/T/S (Topical) is based on data of another medicine with exactly the same composition as the A/T/S (Topical) of the medicine (Erythromycin). Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug A/T/S (Topical) directly from the package or from the pharmacist at the pharmacy.
more... close

In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of A/T/S (Topical)™ Ophthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection.

For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.

Contraindications

The information provided in Contraindications of A/T/S (Topical) is based on data of another medicine with exactly the same composition as the A/T/S (Topical) of the medicine (Erythromycin). Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug A/T/S (Topical) directly from the package or from the pharmacist at the pharmacy.
more... close

This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

Special warnings and precautions for use

The information provided in Special warnings and precautions for use of A/T/S (Topical) is based on data of another medicine with exactly the same composition as the A/T/S (Topical) of the medicine (Erythromycin). Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug A/T/S (Topical) directly from the package or from the pharmacist at the pharmacy.
more... close

WARNINGS

No information provided.

PRECAUTIONS

General

The use of antimicrobial agents may be associated with the overgrowth of nonsusceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted. No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies.

Pregnancy

Teratogenic effects -Pregnancy category B

Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.

Nursing Mothers

Caution should be exercised when erythromycin is administered to a nursing woman.

Pediatric Use

See INDICATIONS and DOSAGE AND ADMINISTRATION.

Undesirable effects

The information provided in Undesirable effects of A/T/S (Topical) is based on data of another medicine with exactly the same composition as the A/T/S (Topical) of the medicine (Erythromycin). Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug A/T/S (Topical) directly from the package or from the pharmacist at the pharmacy.
more... close

The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions.

To report SUSPECTED ADVERSE REACTIONS, contact Fera Pharmaceuticals, LLC at (414) 434-6604 Monday-Friday 9am-5pm EST or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Overdose

The information provided in Overdose of A/T/S (Topical) is based on data of another medicine with exactly the same composition as the A/T/S (Topical) of the medicine (Erythromycin). Be careful and be sure to specify the information on the section Overdose in the instructions to the drug A/T/S (Topical) directly from the package or from the pharmacist at the pharmacy.
more... close

No information provided.